Ocera Therapeutics (OCRX -15.8%) prices its public offering of 4.2M shares of common stock at $6.00 per share. Underwriters over-allotment is 630K shares. Proceeds will be used to advance the clinical programs of OCR-002, working capital and general corporate purposes.
"We believe the combination of palatable clinical development risk, steady data/news flow, strong patent estate, and potential to meaningfully improve the treatment algorithm in an already greater than $1B HE market opportunity with a rapidly expanding patient demographic creates a highly favorable risk/reward at these levels," analyst Stephen Willey says.
joeg1969+ FollowFollowing- Unfollow|Send Message10 Feb 2013
: Definetly !!!!!!!!!!!!Willl see how things play out for a bit before adding .......
joe kelly+ FollowFollowing- Unfollow|Send Message10 Feb 2013
: Bought some last week.
smokeyRose+ FollowFollowing- Unfollow|Send Message15 Nov 2012
Boy am i glad i sold my OCRX yesterday for $4.00 dropped to .99 cents today on Negative news. WOW!!!!
View all 2 replies
Ocean Man+ FollowFollowing- Unfollow|Send Message15 Nov 2012
: You posted 18 Stocktalks yesterday, yet failed to mention that....
smokeyRose+ FollowFollowing- Unfollow|Send Message16 Nov 2012
: Should I have? Had no idea it was going to do that. just lucky I guess
OCRX vs. ETF Alternatives
Ocera Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.